Corinne Haioun
#154,896
Most Influential Person Now
Researcher ORCID ID = 0000-0003-0095-5379
Corinne Haioun's AcademicInfluence.com Rankings
Corinne Haiouncomputer-science Degrees
Computer Science
#8449
World Rank
#8882
Historical Rank
Computational Linguistics
#1885
World Rank
#1905
Historical Rank
Machine Learning
#3463
World Rank
#3506
Historical Rank
Artificial Intelligence
#3763
World Rank
#3818
Historical Rank
Corinne Haiounmathematics Degrees
Mathematics
#7139
World Rank
#9765
Historical Rank
Measure Theory
#1896
World Rank
#2311
Historical Rank
Download Badge
Computer Science Mathematics
Corinne Haioun's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Mathematics Université Paris Cité
Similar Degrees You Can Earn
Why Is Corinne Haioun Influential?
(Suggest an Edit or Addition)Corinne Haioun's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma (2003) (1074)
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (2011) (964)
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. (1998) (931)
- Report on the First International Workshop on interim-PET scan in lymphoma (2009) (603)
- Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. (2011) (521)
- Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). (1998) (503)
- [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. (2005) (501)
- Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). (1996) (484)
- Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. (2000) (453)
- Prognostic significance of survivin expression in diffuse large B-cell lymphomas. (2000) (417)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
- Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. (2011) (384)
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. (2011) (383)
- Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis (2007) (383)
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. (2008) (321)
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial (2011) (314)
- Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (304)
- Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. (2008) (299)
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial (2014) (289)
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network (2016) (289)
- Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. (1990) (288)
- SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. (2011) (288)
- Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. (2014) (269)
- Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma (2017) (261)
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (2013) (256)
- Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. (1993) (253)
- Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. (2004) (246)
- Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2006) (245)
- Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy (2009) (232)
- An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax (2013) (231)
- Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL): A New Diagnostic Marker Providing Evidence That AITL Derives From Follicular Helper T Cells (2006) (230)
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. (2013) (229)
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (2018) (222)
- Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. (1995) (221)
- Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. (2016) (221)
- CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. (1996) (215)
- Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. (2016) (207)
- Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. (1994) (207)
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. (2015) (197)
- Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. (2013) (193)
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients (2000) (189)
- Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. (1995) (189)
- Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. (2016) (185)
- Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma (2014) (181)
- Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). (1993) (180)
- Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. (2012) (175)
- Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study (2016) (174)
- Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma (2014) (170)
- Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. (2006) (169)
- Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. (1990) (159)
- Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. (2012) (156)
- Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma (2010) (154)
- Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. (2012) (153)
- Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas (2009) (153)
- Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma (1996) (150)
- Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. (2014) (142)
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. (2003) (142)
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma (2014) (140)
- Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. (2007) (140)
- Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. (2008) (139)
- Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. (2019) (135)
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. (2017) (135)
- Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study (2007) (134)
- Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus (2012) (133)
- Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. (2017) (133)
- Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. (2010) (127)
- Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin (2017) (126)
- Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010 (2010) (125)
- The MAL gene is expressed in primary mediastinal large B-cell lymphoma. (1999) (125)
- Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. (2004) (124)
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. (2015) (123)
- Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. (2009) (122)
- Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial (2013) (117)
- Presence of HTLV‐I proviral DNA in patients with adult T‐Cell leukemia/lymphoma in Taiwan (1988) (116)
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study (2013) (111)
- A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. (2013) (110)
- Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. (2017) (110)
- A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts (2018) (107)
- Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. (2018) (106)
- Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. (1997) (103)
- p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. (2002) (102)
- Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. (2005) (101)
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab (2008) (98)
- International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. (2020) (98)
- Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. (1997) (96)
- The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association (2015) (96)
- Rituximab ( Anti-CD 20 Monoclonal Antibody ) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma : A Multicenter Phase II Study (1998) (95)
- Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. (2003) (94)
- Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers (2017) (93)
- Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012 (2014) (93)
- A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (2013) (93)
- MR appearance of multiple myeloma of the spine before and after treatment. (1993) (92)
- Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. (2014) (92)
- Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. (2007) (91)
- Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy (2013) (90)
- Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background (2010) (90)
- Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. (2018) (86)
- Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets (2015) (86)
- Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). (2016) (86)
- Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma (2016) (83)
- Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center. (1999) (81)
- Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma: Pilot Study (2011) (81)
- Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA (2011) (81)
- Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. (2010) (81)
- Peripheral T‐cell lymphoma presenting as predominant liver disease: A report of three cases (1986) (81)
- Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. (2006) (80)
- The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development (2016) (79)
- FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. (2017) (78)
- Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. (2019) (77)
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma (2016) (77)
- Bone Marrow Involvement in Lymphomas With Hemophagocytic Syndrome at Presentation: A Clinicopathologic Study of 11 Patients in a Western Institution (2001) (76)
- Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. (2003) (76)
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. (2000) (75)
- Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA (2012) (75)
- Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. (2018) (74)
- Flow Cytometric Immunophenotyping of Cerebrospinal Fluid (2008) (73)
- Impact of high-dose chemotherapy on peripheral T-cell lymphomas. (2002) (72)
- Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. (2017) (72)
- Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics (2012) (71)
- Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. (2019) (70)
- The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages (2009) (68)
- Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases (2016) (68)
- All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2004) (68)
- Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. (2010) (67)
- R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study (2009) (67)
- Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. (2017) (67)
- Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? (2005) (66)
- Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. (2009) (66)
- Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. (2015) (65)
- Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate (2009) (64)
- Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. (2004) (62)
- Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. (2012) (61)
- Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type (2001) (60)
- Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014 (2015) (60)
- Bone marrow histologic and immunohistochemical findings in peripheral. T-cell lymphoma: A study of 38 cases. (1991) (59)
- A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts (2018) (58)
- Low grade B cell mucosa associated lymphoid tissue lymphoma of the stomach: clinical and endoscopic features, treatment, and outcome. (1992) (57)
- EZH2 alterations in follicular lymphoma: biological and clinical correlations (2017) (57)
- Lethal midline granuloma (polymorphic reticulosis) and lymphomatoid granulomatosis. Evidence for a monoclonal T-cell lymphoproliferative disorder. (1988) (54)
- Mediastinal Diffuse Large‐Cell Lymphoma with Sclerosis: A Condition with a Poor Prognosis (1989) (54)
- Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients. (1991) (54)
- Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients (2007) (54)
- Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). (2018) (54)
- Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant (2016) (52)
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. (2019) (51)
- Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2010) (51)
- Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. (2015) (50)
- Management and outcome of primary CNS lymphoma in the modern era (2020) (50)
- Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. (2004) (50)
- Association of primary pleural effusion lymphoma of T-cell origin and human herpesvirus 8 in a human immunodeficiency virus-seronegative man. (2009) (49)
- Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma (2009) (49)
- Characterization of CXCL13+ Neoplastic T Cells in Cutaneous Lesions of Angioimmunoblastic T-cell Lymphoma (AITL) (2007) (48)
- Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. (2018) (48)
- Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years. (2006) (48)
- Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. (2012) (47)
- Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials (2018) (46)
- Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study (2000) (46)
- Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand? (2009) (46)
- Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years (2017) (46)
- [18F]-FDG positron imaging in clinical management of lymphoma patients. (2001) (45)
- A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma (2016) (45)
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. (2012) (44)
- Comparison of genetic probe with immunophenotype analysis in lymphoproliferative disorders: a study of 87 cases. (1988) (43)
- Recombinative events of the T cell antigen receptor delta gene in peripheral T cell lymphomas. (1991) (43)
- Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. (1999) (43)
- Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma (2012) (43)
- Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. (2016) (42)
- Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). (2000) (42)
- Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group (2016) (42)
- Sarcoidosis Occurring After Lymphoma (2014) (41)
- Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging. (2015) (41)
- Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. (2012) (40)
- Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma (2013) (40)
- Whole-body diffusion-weighted imaging in lymphoma (2010) (39)
- Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma (2016) (39)
- Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up (2010) (39)
- Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma (2013) (38)
- Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study (2014) (37)
- Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. (1994) (37)
- Use of Model-Based Iterative Reconstruction (MBIR) in reduced-dose CT for routine follow-up of patients with malignant lymphoma: dose savings, image quality and phantom study (2015) (37)
- Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. (2001) (37)
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma (2018) (37)
- European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma (2016) (36)
- Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003) (2008) (35)
- The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. (2012) (35)
- Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study. (2017) (35)
- New insights into breast implant-associated anaplastic large cell lymphoma (2018) (34)
- Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. (2020) (33)
- Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma (2020) (33)
- Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. (2009) (32)
- Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. (1994) (31)
- Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. (2012) (30)
- Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups (2013) (30)
- Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). (2013) (29)
- Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas (2016) (29)
- Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients (2016) (29)
- Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study (2018) (28)
- Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study (2013) (28)
- RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA (2008) (28)
- Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. (2007) (27)
- Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices? (2012) (27)
- Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). (2011) (27)
- PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma (2015) (26)
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. (2015) (25)
- Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study (2008) (25)
- Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders (2014) (25)
- Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes (2019) (24)
- Chronic hepatitis C virus and gastric MALT lymphoma. (1998) (24)
- Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management (2014) (24)
- Secondary Pancreatic Involvement by Diffuse Large B-Cell Lymphoma Presenting as Acute Pancreatitis: Treatment and Outcome (2011) (24)
- Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles (2019) (24)
- Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93 (1997) (24)
- Report of the 6th International Workshop on PET in lymphoma (2017) (24)
- Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003). (2009) (23)
- Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. (2011) (23)
- Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. (1993) (23)
- Hepatitis C virus infection, mixed cryoglobulinemia, and B‐cell non‐Hodgkin's lymphoma (1999) (23)
- Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. (2021) (23)
- Whole body MRI and PET/CT in haematological malignancies (2007) (22)
- A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. (2012) (22)
- Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. (2021) (22)
- A multivariate analysis of the survival of patients with aggressive lymphoma (1998) (22)
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. (2004) (22)
- Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL (2010) (21)
- Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution. (2005) (21)
- A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. (1998) (21)
- Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing. (2018) (20)
- Duodenal mucosa-associated lymphoid tissue lymphoma: treatment with oral cyclophosphamide (2000) (20)
- Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience. (2009) (20)
- IL-12 Secreting Dendritic Cells are Required for Optimum Activation of Human Secondary Lymphoid Tissue T Cells (2002) (19)
- Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma (2017) (19)
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up (2007) (19)
- Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas (2017) (19)
- Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. (2018) (19)
- High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. (1998) (19)
- [Non epidermotropic T lymphoma preceded for several years by hypereosinophilic syndrome]. (1990) (19)
- Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma (2007) (19)
- BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial (2017) (19)
- Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma. (2006) (18)
- Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2013) (18)
- First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa (2016) (18)
- Primary thrombocythaemia associated with systemic mastocytosis: a report of five cases (1991) (17)
- Clinical and biological analysis of peripheral T-cell lymphomas: a single institution study. (1992) (17)
- 10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma. (2009) (17)
- Hepatosplenic T-cell Lymphoma : Sinusal / Sinusoidal Localization of Malignant Cells Expressing the T-cell Receptor y 6 (2003) (17)
- POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (2017) (16)
- Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab. (2009) (16)
- Frequent and Rapid Progression of Atrophy and Intestinal Metaplasia in Gastric Mucosa of Patients with MALT Lymphoma (2006) (16)
- A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B (2010) (16)
- Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study. (2012) (16)
- Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years. (2004) (16)
- Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial (2010) (16)
- Successful Long‐Term Outcome of the First Combined Heart and Kidney Transplant in a Patient with Systemic AL Amyloidosis (2008) (16)
- Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies (2016) (16)
- Rituximab, alkylating agents or combination therapy for gastric mucosa‐associated lymphoid tissue lymphoma: a monocentric non‐randomised observational study (2014) (16)
- Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) (2010) (15)
- SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL). (2006) (15)
- Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay (2017) (15)
- Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial--A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2010) (15)
- Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999), (2011) (15)
- Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study (2019) (15)
- The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. (2021) (15)
- Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. (2017) (15)
- Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) (2007) (15)
- Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma (2018) (15)
- [Intravascular large cell lymphoma revealed by diffuse telangiectasia and cauda equina syndrome]. (2002) (14)
- Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. (2000) (14)
- Liver transplantation for fulminant hepatitis following chemotherapy for malignant lymphoma (1990) (14)
- Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study (2018) (14)
- Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. (2001) (14)
- Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant (2011) (14)
- SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) (2004) (13)
- Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study. (2005) (13)
- Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05 (2010) (13)
- Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (2017) (13)
- Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study (2016) (13)
- Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma (2017) (12)
- Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study (2008) (12)
- Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study (2011) (12)
- Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma (2015) (12)
- FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts (2017) (12)
- Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study. (2013) (12)
- Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. (2007) (12)
- Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. (2017) (11)
- Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma (2020) (11)
- Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study (2019) (11)
- Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. (2016) (11)
- Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies (2018) (11)
- Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation (2021) (10)
- Intensifi ed chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma ( LNH 032 B ) : an open-label randomised phase 3 trial (2011) (10)
- Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis. (2019) (10)
- Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma (2015) (10)
- SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL (2019) (9)
- Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. (2019) (9)
- PET scan in the therapeutic strategy. (2004) (9)
- Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy. (2010) (9)
- Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. (2012) (9)
- Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. (2008) (9)
- Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma (2016) (9)
- Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program. (2010) (9)
- Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy. (2021) (9)
- Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. (2001) (9)
- High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial (2010) (8)
- Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma. (2004) (8)
- Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study. (2006) (8)
- Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe (2012) (8)
- Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study (2007) (8)
- Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial (2017) (8)
- Folliculotropic T‐cell infiltrates associated with B‐cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature (2015) (8)
- Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies (2022) (8)
- Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study (2018) (8)
- R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B (2011) (7)
- Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens. (2009) (7)
- R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study. (2012) (7)
- Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa (2019) (7)
- CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (2017) (7)
- Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis (2021) (7)
- Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin ' s lymphomas (2000) (7)
- Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies (2016) (7)
- Efficacy and Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results of the Interim Analysis of the LNH03-6B GELA Study. (2009) (7)
- Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients. (2004) (7)
- Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study. (2007) (7)
- Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL) (2012) (7)
- Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (2021) (6)
- Efficiency of In Vivo Purging With Rituximab Followed by High-Dose Therapy With Autologous Peripheral Blood Stem Cell Transplantation in B-Cell Non-Hodgkin’s Lymphomas: A Single-Institution Study (2001) (6)
- Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (2010) (6)
- Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma (2021) (6)
- Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). (2009) (6)
- Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA. (2020) (6)
- EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL (2021) (6)
- Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin’s lymphoma (NCT00796731). (2012) (6)
- A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort (2021) (6)
- Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA (2020) (6)
- [Systemic capillary leak syndrome disclosing mixed diffuse T lymphoma]. (1991) (6)
- Darier's sign in cutaneous large T-cell lymphoma. (1996) (6)
- Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study (2010) (6)
- Duodenal mucosa-associated lymphoid tissue lymphoma: treatment with oral cyclophosphamide. (2000) (6)
- Expression of the alpha beta and gamma delta T-cell receptors in peripheral T-cell lymphomas. (1990) (5)
- Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B) (2014) (5)
- Clinical impact of contrast-enhanced computed tomography (CECT) combined with low-dose FDG PET/CT on lymphoma patient management (2012) (5)
- Colonic mucosa-associated lymphoid tissue lymphoma: a case series (2019) (5)
- A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. (2010) (5)
- Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study. (2021) (5)
- Rituximab and Reduced Dose CHOP (R-mini-CHOP) for Patients Over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-7B (2010) (5)
- Extensive telangiectases of the scalp: atypical presentation of primary cutaneous follicle centre lymphoma (2012) (5)
- A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. (2010) (5)
- Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma. (2006) (5)
- A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma (2016) (5)
- ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies (2017) (5)
- A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B‐CELL LYMPHOMA (2017) (5)
- Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. (2012) (5)
- MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d'Etude Des Lymphomes De l'Adulte (2012) (5)
- A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL) (2014) (4)
- Effect of Rituximab and/or High-Dose Therapy with Autotransplant at Time of Relapse in Patients with Follicular Lymphoma. (2007) (4)
- The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003). (2008) (4)
- Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients. (2001) (4)
- Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma. (2008) (4)
- Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years (2021) (4)
- Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R)CHOP (2013) (4)
- Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study. (2006) (4)
- Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study (2015) (4)
- Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL). (2014) (4)
- Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data. (2018) (4)
- Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC) (2019) (4)
- IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era (2013) (4)
- Long Term Follow-up of the GELF86 French and Belgian Trials : Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission. (2008) (4)
- Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma (2021) (4)
- [Whole body functional MR imaging: hemato-oncologic applications]. (2010) (4)
- Impact of rituximab on stem cell mobilization following ACVBP regimen in poor‐risk patients with diffuse large B‐cell lymphoma: results from a large cohort of patients (2013) (4)
- Autologous Stem Cell Transplantation (auto-SCT) as the Treatment of Choice for Follicular Lymphoma Patients in First Relapse: Final Analysis of the Outcome of 175 Patients Treated in the GELA/GOELAMS FL 2000 Study (2008) (4)
- Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. (2021) (4)
- Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment (2020) (4)
- CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria (2019) (4)
- Lenalidomide As Maintenance Therapy after R-CHOP Has No Protecting Effect for Central Nervous System Relapse in Frontline Treatment of Diffuse Large B-Cells Lymphoma. an Ancillary Studies of the Remarc Study (2020) (3)
- High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience. (2001) (3)
- Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B ) (2013) (3)
- S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM (2019) (3)
- Immunoblastic lymphoma involving the bone marrow in a patient with alpha chain disease. Clinical and immunoelectron microscopic study (1985) (3)
- Phase II study of PEG-Intron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated. (2004) (3)
- [Primary cutaneous lymphoma, with the exception of mycosis fungoides]. (1992) (3)
- Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance (2021) (3)
- [Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]. (2017) (3)
- Original Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study (2005) (3)
- R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers (2020) (3)
- POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). (2020) (3)
- prospective Phase Ii Trial Of Lenalidomide In Association With Chop In Elderly Patients With Angioimmunoblastic T Cell Lymphoma (aitl): Interim Analysis Of A Lysa Study : 101 (2015) (3)
- Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3). (2009) (3)
- Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas (2011) (3)
- Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies. (2014) (3)
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial (2019) (3)
- Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL). (2019) (3)
- A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) (2016) (3)
- POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies (2019) (3)
- [Treatment of large-cell gastric lymphoma: comparison of the efficacy of radiochemotherapy alone or combined with first gastrectomy]. (1996) (3)
- Prolonged Remission After TPO-Receptor Agonist Discontinuation In Adults With Chronic ITP. Results Of a French Observational Study (2013) (3)
- Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials (2017) (3)
- Early Response Evaluation with 18FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma. (2005) (3)
- Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project (2020) (3)
- Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin (2020) (3)
- [CD30 (Ki-1+) anaplastic large cell lymphomas]. (1989) (3)
- Hematopoietic growth factors in treatment of necrotizing cellulitis patients with drug-induced neutropenia. (1993) (3)
- Can Rituximab be Useful for Treating SLE-Associated Immune Cytopenias ? Results from a Retrospective Multicentre Study on 62 Patients (2016) (2)
- Failure of Combination Chemotherapy of Advanced Follicular (Low‐Grade) Non‐Hodgkin's Lymphoma (1987) (2)
- Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study (2011) (2)
- Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients (2016) (2)
- Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma. (2017) (2)
- A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists (2015) (2)
- Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies (2015) (2)
- Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study (2018) (2)
- Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case-Control Comparison With Intravenous Rituximab. (2020) (2)
- Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients (2012) (2)
- Benefit of the Adjunction of Rituximab in Salvage Regimen before Autologous Stem-Cell Transplantation (ASCT) in Follicular Lymphoma at Relapse. A Single Institution Study. (2005) (2)
- Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (2022) (2)
- A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study (2013) (2)
- Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study (2018) (2)
- Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. (2017) (2)
- Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93. (1997) (2)
- Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study. (2016) (2)
- Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab. (2005) (2)
- Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data (2018) (2)
- A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy (2018) (2)
- Outcomes after fi rst-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study (2021) (2)
- [Leg ulcer associated with type I cryoglobulinaemia due to incipient B-cell lymphoma]. (2013) (2)
- des Lymphomes de l'Adulte (GELA) trials angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude Clinical, biologic, and pathologic features in 157 patients with (2013) (2)
- Reply to H.J.A. Adams et al and E. Laffon et al. (2017) (2)
- A New Immunohistochemical Algorithm Using Four Antibodies Has a High Concordance with Gene Expression Profiling Defined ABC and GCB Diffuse Large B-Cell Lymphoma (2017) (2)
- Rituximab maintenance after autologous stem‐cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group (2017) (2)
- Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts). (2021) (2)
- [Non-Hodgkin lymphoma in the elderly]. (2008) (2)
- Long-term follow-up of high-dose treatment (HDT) with autologous haematopoietic progenitor cell support in 702 patients (pts.) with follicular lymphoma (FL). An EBMT registry study. (2006) (2)
- GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY (2021) (1)
- Analysis of the intraclonal diversity of HLA‐A0201‐restricted T lymphocyte epitopes in follicular lymphoma idiotype (2005) (1)
- Inhibition of Hedgehog Signaling for the Treatment of Lymphoma and CLL: A Phase II Study from the Lysa (2015) (1)
- 1140 POSTER Epoetin beta therapy in anemic patients with solid tumor or non myeloid hematological malignancies receiving chemotherapy: results of a large prospective cohort study (2007) (1)
- Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin (2018) (1)
- PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS (2017) (1)
- BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL (2019) (1)
- Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma (2013) (1)
- Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). (2022) (1)
- Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts) (2021) (1)
- Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study (2021) (1)
- Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma (2022) (1)
- PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38) (2021) (1)
- Brentuximab Vedotin in refractory or relapsed Peripheral T-cell Lymphoma: The French name patient program experience in 66 patients (2015) (1)
- Compliance with ASCO 2006 recommendations for the use of "white blood cell growth factors" in advanced lung cancer (LC) or breast cancer (BC) or non-Hodgkin lymphoma (NHL): An interim analysis of French National Observational Study—The ZOHé study. (2014) (1)
- Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma (2019) (1)
- Correlation between RNA and protein levels in a large european series from the LYSA (2013) (1)
- Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T 3 Phase IB Trial of the Lysa Group (2016) (1)
- Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA. (2021) (1)
- Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas (1990) (1)
- Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations (2014) (1)
- Characteristics and Outcome of Newly Diagnosed Immune Thrombocytopenia in Adults: Results from a Nationwide Prospective Cohort Study (2015) (1)
- PS1410 DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT (2019) (1)
- Percutaneous Fine Needle Aspiration Cytology and Biopsy in the Diagnosis and Classification of Lymphoma: Clinical Evaluation. (1991) (1)
- [Clinical research activity of the French cancer cooperative network: Overview and perspectives]. (2017) (1)
- Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study (2021) (1)
- Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma (2021) (1)
- Lenalidomide Plus Bortezomib and Dexamethasone (RVD) Followed by Lenalidomide Plus Dexamethasone As Salvage Treatment for Myeloma Patients in First Relapse After Autologous Stem Cell Transplantation. Single Institution Experience (2011) (1)
- Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. (2012) (1)
- Epoetin beta treatment of chemotherapy induced anemia in cancer patients: Results of a large prospective cohort study (2007) (1)
- CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY (2021) (1)
- Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study (2017) (1)
- Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa (2020) (1)
- Epstein–Barr virus‐associated B‐cell lymphoproliferative disorder in a patient with Sézary syndrome treated by methotrexate (2016) (1)
- Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study (2008) (1)
- Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study (2015) (1)
- Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study (2013) (1)
- Influence of translocation t(11;18) on response to conservative treatment of MALT gastric lymphoma (MGL) (2003) (1)
- Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study (2014) (1)
- Congenital Erythropoietin-Dependent Erythrocytosis Responsive to Theophylline Treatment (1998) (1)
- Peripheral T-Cell Lymphomas with Follicular Growth Patterns Are Derived from Follicular Helper T Cells (TFH): A Link with Angioimmunoblastic T-Cell Lymphomas?. (2007) (1)
- Non-Interventional Retrospective Multicenter Study Evaluating Real Word Idelalisib Use in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Patients Enrolled in the French Early Access Program (2018) (1)
- Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients (2003) (1)
- Lymphomes agressifs : Lymphomes de l'adulte (2002) (1)
- Single nucleotide polymorphisms in ABCB 1 and CBR 1 can predict toxicity to R-CHOP type regimens in patients with diffuse non Hodgkin lymphoma by (2015) (1)
- Rituximab plus gemcitabine and oxaliplatine (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study. (2010) (1)
- transplantation in aggressive lymphomas Pregnancies after high-dose chemotherapy and autologous stem cell (2012) (1)
- Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study. (2007) (1)
- An international validation study of the prognostic role of interim FDG PET/CT in diffuse large B-cell lymphoma (2012) (1)
- Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma (2016) (1)
- Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study (2021) (1)
- RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN (R‐GemOx) IN REFRACTORY/RELAPSED (R/R) DLBCL. A REAL LIFE STUDY IN PATIENTS INELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (2019) (1)
- Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial (2022) (1)
- CNS prophylaxis in diffuse large B-cell lymphoma – Authors' reply (2012) (1)
- Farnesyltransferase Inhibitor Tipifarnib (Zarnestra) in Refractory Mantle Cell Lymphoma (MCL): A Therapeutic Target Only for Specific Patients Categorized by the 2-Gene Classifier for Predictive Response to Tipifarnib. (2008) (1)
- Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL). (2010) (0)
- Anaplastic large cell lymphomas associated with breast implants: from diagnosis to molecular sequencing (2020) (0)
- THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS (2019) (0)
- Oral Abstract: ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts) (2021) (0)
- POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2021) (0)
- Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study (2022) (0)
- The diversity of p53/p21 transactivation phenotype of p53 signaling pathway and their relationship to TP53 gene mutation and clinical outcome in diffuse large B-cell lymphoma (DLBCL) (2007) (0)
- [Gastric lymphoma: role of Helicobacter pylori]. (1997) (0)
- Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study (2023) (0)
- lymphomas Prognostic significance of survivin expression in diffuse large B-cell (2013) (0)
- Functional Imaging in Lymphoma (2014) (0)
- Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy (2021) (0)
- PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients (2011) (0)
- GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS (2021) (0)
- Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study (2021) (0)
- ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA (2021) (0)
- Clinical Spectrum, Evolution and Management of Autoimmune Cytopenia Associated with Angioimmunoblastic T-Cell Lymphoma: A Retrospective, Multicenter Study (2016) (0)
- Gastric malt lymphoma : a pathogenetic role of hepatitis C virus (HCV)? (1998) (0)
- Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring (2018) (0)
- BCL2 Negative Follicular Lymphoma with BCL6 Gene Rearrangement Show Mutations of STAT6 DNA Binding Domain (2012) (0)
- Cost Effectiviness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia. (2012) (0)
- Ancestim (stem cell factor, SCF) in combination with filgrastim can mobilize sufficient peripheral blood progenitor cells (PBPC) to support high-dose salvage chemotherapy and late intensification in relapsing and refractory aggressive non-Hodgkin's lymphoma. A GELA study. (2003) (0)
- The usefulness of phenotypic and genotypic studies in malignant lymphoma and related disorders. (1989) (0)
- Epoetin Beta (Neorecormon®) Treatment for Anemia of Patients with Non-Myeloid Hematological Malignancy under Chemotherapy: Results of a Large Prospective Cohort Study. (2007) (0)
- Overt B-cell non-Hodgkin's lymphoma (B-NHL): Role of hepatitis C virus (HCV) (2000) (0)
- EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients (2022) (0)
- Cytokine Gene Polymorphisms and Outcome of Patients with Hodgkin Lymphoma: A Prospective Study of the Groupe D’Etude Des Lymphomes De L’Adulte (2008) (0)
- [Treatment of gastric lymphomas. The role of surgery must be revisited]. (1992) (0)
- Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial (2020) (0)
- Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort (2019) (0)
- LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R‐CHOP: UPDATE OF THE LNH03‐6B TRIAL (2021) (0)
- HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS (2009) (0)
- Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. (2023) (0)
- Long-Term Outcome of B-CLL Patients Treated in a Prospective Trial Evaluating Combination of Oral Fludarabine and Cyclophosphamide As Frontline Therapy (2011) (0)
- Characteristics and Outcome of DAT-Negative Autoimmune Hemolytic Anemia: Results from a French Multicentre Observational Study (2018) (0)
- EPH145 Treatment Patterns Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Ineligible for Transplantation – A Real-World Study Using French PMSI (2022) (0)
- P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. (2022) (0)
- Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study (2022) (0)
- EZH2 alterations in follicular lymphoma: biological and clinical correlations (2017) (0)
- Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. (2021) (0)
- Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma (2015) (0)
- Cutaneous Tumor of the Arm Revealing a Sporadic Burkitt Lymphoma (2016) (0)
- Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP. (2008) (0)
- RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY (2019) (0)
- Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial (2022) (0)
- METABOLIC TUMOR IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R ‐ CHOP – FROM REMARC, A LYSA STUDY (2021) (0)
- Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study. (2022) (0)
- Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte (2009) (0)
- Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies (2016) (0)
- Quality of life in 269 poor-risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial. (2010) (0)
- INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY (2017) (0)
- Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Program LNH2003, (2011) (0)
- Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients (2013) (0)
- Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma (2015) (0)
- Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study (2023) (0)
- Gastric malt lymphoma: Pathogenetic role of hepatitis C virus (1998) (0)
- The 5 Th InTernaTIonal Workshop on posITron emIssIon Tomography In lymphoma Report on the 5 th International Workshop on Positron Emission Tomography in Lymphoma held in Menton , France , 19 – 20 September 2014 (2015) (0)
- The importance of G-CSF prophylaxis in R-CHOP-14 therapy for diffuse large B-cell lymphoma in routine clinical practice (2017) (0)
- Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study (2020) (0)
- indolent lymphoma 309 QUALITY OF LIFE MEASURES IN ‘ASYMPTOMATIC’ PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT PRESENTATION (2008) (0)
- LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY (2017) (0)
- BASELINE CIRCULATING CELL‐FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA (2017) (0)
- lymphoproliferative disorders: a study of 87 cases Comparison of genetic probe with immunophenotype analysis in (2011) (0)
- A sufficient reduction of SUVmax detected on early FDG-PET during induction therapy is an independent prognostic indicator in diffuse large B-cell lymphoma (DLBCL) (2008) (0)
- CLINICAL, IMMUNOPHENOTYPIC AND GENETIC CHARACTERISTICS OF AGGRESSIVE (NON‐BURKITT) B‐CELL LYMPHOMA IN A REAL LIFE COHORT (2019) (0)
- MRI and PET of bone marrow in lymphoproliferative diseases (2003) (0)
- Anemia and darbepoetin alfa administration in patients treated with chop+/-r chemotherapy: results from an observational study of patients with non-hodgkin lymphoma (2010) (0)
- 623MO Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients (2022) (0)
- Biosimilar filgrastim treatment patterns and relative dose intensity (RDI) maintenance in patients receiving chemotherapy (CT) for the treatment of solid tumor (ST) or lymphoid malignancies (LM): A French national observational study (The ZOHé study). (2015) (0)
- Surgery plus chemotherapy or chemotherapy alone for localized high-grade gastric lymphomas (2000) (0)
- A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults (2015) (0)
- P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE (2022) (0)
- Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa (2022) (0)
- Mediastinal Lymphomas:Prognostic and Therapeutic Management Based on Histology (1985) (0)
- Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study) (2019) (0)
- Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study (2013) (0)
- Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system. (2016) (0)
- Helicobacter pylori and gastric malt lymphoma: Role of the CagA protein (1998) (0)
- EE138 Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI (2022) (0)
- Impact of Rituximab on Peripheral Blood Stem Cell Mobilization and Collection Following ACVBP Regimen in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Large Cohort of Patients from Two Prospective GELA Trials. (2008) (0)
- Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx (2020) (0)
- Pr Bertrand Coiffier (2019) (0)
- Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma (2022) (0)
- Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. (2023) (0)
- Anemia and esa administration in patients treated with rchop chemotherapy: results from an observational study of patients with non-hodgkin lymphoma (2010) (0)
- Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma (2012) (0)
- SUV-based assessment of therapeutic response by FDG-PET during induction chemotherapy in diffuse large B-cell lymphoma (DLBCL) (2008) (0)
- Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation (2019) (0)
- ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B ‐ CELL LYMPHOMA (AAIPI = 0) : RESULTS OF THE PHASE 3 LYSA LNH 1B TRIAL (2021) (0)
- [Non-epidermotropic cutaneous lymphomas]. (1987) (0)
- Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data (2019) (0)
- A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL) (2021) (0)
- Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis. (2023) (0)
- ROLE OF UP‐FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS (2017) (0)
- Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients (2017) (0)
- SERUM 2‐HYDROXYGLUTARATE, A PREDICTIVE BIOMARKER OF THE PRESENCE OF IDH2 MUTATIONS IN AITL PATIENTS (2017) (0)
- Impact of febrile neutropenia on RCHOP chemotherapy delivery and hospitalizations: Results from an international observational study in patients with non-Hodgkin lymphoma (Impact NHL) (2010) (0)
- Conservative treatment is suitable in patients with high-grade gastric lymphoma (1995) (0)
- Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed/Refractory T Cell Lymphomas in Adults: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). (2006) (0)
- Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing (2015) (0)
- study from the GELA patients with advanced follicular lymphoma: the GELF-94 randomized high-dose therapy with autologous stem cell transplantation in untreated Standard chemotherapy with interferon compared to CHOP followed by (2013) (0)
- lymphoma patients: results of the GELA-GOELAMS FL2000 study Rituximab combined with chemotherapy and interferon in follicular (2013) (0)
- Cerebrospinal Fluid Immunophenotyping in B-Cell Lymphomas: A Single Centre Experience on 99 Samples. (2007) (0)
- REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE (2019) (0)
- BASELINE CIRCULATING TUMOUR DNA AND TOTAL METABOLIC TUMOUR VOLUME AS EARLY OUTCOME PREDICTORS IN AGGRESSIVE B‐CELL LYMPHOMA. A REAL LIFE PROSPECTIVE 112‐PATIENT COHORT (2021) (0)
- Paper 81946 abstract 160359 0 (2015) (0)
- High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network (2022) (0)
- P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (2022) (0)
- A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa (2021) (0)
- Baseline Metabolic Tumor Volume predicts outcome in patients with high tumor burden follicular lymphoma. (2016) (0)
- Interleukin 4 -induced gene 1 ( FIG1 ) is activated in primary mediastinal large B cell lymphoma Short running head : FIG1 gene activation in PMBL (2002) (0)
- Risk Factors of Neonatal Immune Thrombocytopenia in Pregnant Women Previously Diagnosed with ITP: Results from a French Nationwide Prospective Study (2020) (0)
- 96 PET imaging of non-Hodgkin lymphoma: defining methodologies for early prediction of response (2009) (0)
- Predictive value of spleen and bone marrow involvement detected on baseline FDG-PET/CT in peripheral T cell lymphoma (PTCL). (2016) (0)
- Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry (2022) (0)
- DIFFUSE LARGE B-CELL LYMPHOMA-ASSOCIATED-RETINOPATHY CHARACTERIZED BY MINIMAL MORPHOLOGIC CHANGES AND SEVERE FUNCTIONAL IMPAIRMENT (2017) (0)
- Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study (2022) (0)
- COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B‐CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT‐LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL (2019) (0)
- IPI24 supplemental material submitted (2015) (0)
- PET/CT Before Autologous Stem Cell Transplantation Predicts Outcome In High-Risk, Relapsed Follicular Lymphoma (2013) (0)
- Oxaliplatin in lymphoma (2009) (0)
- Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBLC). (2007) (0)
- PB1893 NON-INTERVENTIONAL RETROSPECTIVE MULTICENTER STUDY EVALUATING REAL WORD IDELALISIB USE IN CLL AND INHL PATIENTS ENROLLED IN THE FRENCH EARLY ACCESS PROGRAM (EAP) (2019) (0)
- Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study (2021) (0)
- 5059 Epoetin beta therapy in anaemic breast cancer patients receiving chemotherapy: results of a subgroup from a large prospective cohort study (2009) (0)
- l'Adulte (GELA) non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de Prognostic significance of bcl-2 protein expression in aggressive (2002) (0)
- Expression of the Alpha/Beta and Gamma/ Delta T-cell Receptors in 57 Cases of Peripheral T-cell Lymphomas Identification of a Subset of y/6 T-ceII Lymphomas (2007) (0)
- Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03–6B GELA Study. (2012) (0)
- Evaluation avec la TEP-FDG precoce des patients atteints de lymphome agressif a grandes cellules B (DLBCL) (2007) (0)
- [Aggressive lymphomas]. (2020) (0)
- Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma (2020) (0)
- Monochemotheray as treatment of low-grade B-cell gastric mucosa associated lymphoid tissue lymphoma (1995) (0)
- Delayed Severe Neutropenia after Rituximab Therapy in 18 among 293 Patients with B-Cell Malignancies Treated in a Single Institution. an Adverse Event of Unknown Mechanism. (2004) (0)
- Authors' Reply. (2018) (0)
- Interim 18F-Fluorodeoxyglucose PET scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab (2012) (0)
- JAK‐STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI‐ALCL PATHOGENESIS? (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Corinne Haioun?
Corinne Haioun is affiliated with the following schools:
